Cellectis, Takara Bio deal

Cellectis sold its Cellectis AB subsidiary to Takara. The subsidiary is focused on applications of human embryonic stem cell (hES)-based products and technologies. Last year, Cellectis said it would downsize its products and services business to focus on providing services to the bio-pharmaceutical industry and move away from sales of basic tools to academics. The deal with Takara is the last step of its reorganization of the business unit, which recorded an operating loss of EUR14 million ($18.8 million) before extraordinary depreciation and other downsizing costs. The companies did not disclose financial terms of the deal. ...